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The prostate-specific gene, TMPRSS2 is fused with the gene for the transcription factor ERG in a large proportion of human prostate
cancers. The prognostic significance of the presence of the TMPRSS2:ERG gene fusion product remains controversial. We examined
prostate cancer specimens from 165 patients who underwent surgery for clinically localised prostate cancer between 1998 and 2006.
We tested for the presence of TMPRSS2:ERG gene fusion product, using RT–PCR and direct sequencing. We conducted a survival
analysis to determine the prognostic significance of the presence of the TMPRSS2:ERG fusion gene on the risk of prostate cancer
recurrence, adjusting for the established prognostic factors. We discovered that the fusion gene was expressed within the prostate
cancer cells in 81 of 165 (49.1%) patients. Of the 165 patients, 43 (26.1%) developed prostate-specific antigen (PSA) relapse after a
mean follow-up of 28 months. The subgroup of patients with the fusion protein had a significantly higher risk of recurrence (58.4% at
5 years) than did patients who lacked the fusion protein (8.1%, Po0.0001). In a multivariable analysis, the presence of gene fusion was
the single most important prognostic factor; the adjusted hazard ratio for disease recurrence for patients with the fusion protein was
8.6 (95% CI¼3.6–20.6, Po0.0001) compared to patients without the fusion protein. Among prostate cancer patients treated with
surgery, the expression of TMPRSS2:ERG fusion gene is a strong prognostic factor and is independent of grade, stage and PSA level.
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The surgical treatment of localised prostate cancer has been shown
to improve prostate cancer-specific mortality (Bill-Axelson et al,
2005); however, for many patients with prostate cancer the course
is indolent, and in the absence of surgery, many do not experience
disease progression to metastasis or death (Albertsen et al, 1998).
Currently, the established prognostic factors (histologic grade,
stage and prostate-specific antigen (PSA) level at diagnosis
(Albertsen et al, 1998; Barry et al, 2001) are insufficient to
separate prostate cancer patients who are at high risk for cancer
progression from those who are likely to die of another cause. If
it were available, a predictive marker would allow physicians to
maximise the benefits, and to minimise the side effects, of surgery
and of other treatments. To date, molecular markers for prostate
cancer progression remain elusive. This is in contrast to the
situation for other malignancies, such as breast cancer, where
molecular-based prognostic markers have revolutionised treat-
ment (Seidman, 2006).
Potentially useful genetic markers for prostate cancer progres-
sion have been identified through gene array analysis. Tomlins
et al (2005) identified the overexpression of ERG (21q22.3) and
ETV1 (7p21.2) in prostate cancer tumour cells after DNA fusion
with a prostate-specific gene, TMPRSS2. ERG and ETV1 proteins
are members of the ETS family of transcription factors, which are
important in several oncogenic pathways (Watson et al, 2002; Seth
and Watson, 2005). The TMPRSS2 protein is a serine protease that
is highly expressed in both normal and cancerous prostate cells,
and expression is regulated by androgens (Lin et al, 1999; Afar
et al, 2001). In many cases, the promoter/enhancer region of the
TMPRSS2 gene was found to be fused to the coding region of
one of the ETS transcription factors, ERG or ETV1. Expression
of the fusion gene was found in prostate cancer cell lines, and
from prostate cancer tissue obtained from radical prostatectomy
specimens.
The potential utility of the TMPRSS2:ERG fusion product as
an independent prognostic marker for patients with clinically
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slocalised prostate cancer remains controversial. Several studies
have compared clinicopathological parameters (Perner et al, 2006;
Wang et al, 2006; Lapointe et al, 2007; Rajput et al, 2007; Tu et al,
2007) and prognostic significance (Wang et al, 2006; Attard et al,
2007; Demichelis et al, 2007; Lapointe et al, 2007; Nam et al, 2007)
of this gene fusion with conflicting results. Two of these studies
showed no correlation between histologic grade (Gleason score)
(Lapointe et al, 2007; Tu et al, 2007), while others found positive
associations (Attard et al, 2007; Rajput et al, 2007). Also, some
studies have only shown correlation of fusion status with tumour
stage (Perner et al, 2006; Wang et al, 2006). Wang et al (2006)
examined 119 patients for fusion status from a case–control
approach and found significant correlations with tumour stage,
but no associations were found with early recurrence. Further,
Lapointe et al (2007) in another case–control study found no
correlations with any clinicopathological parameter and recurrence-
free survival.
However, two cohort studies of men with clinically localised
prostate cancer who did not undergo treatment (i.e. watchful
waiting) showed that men who had TMPRSS2:ERG fusion had
lower prostate cancer-specific survival compared to men without
fusion expression (Attard et al, 2007; Demichelis et al, 2007).
Patients managed and selected for watchful waiting from these
cohorts have different baseline distributions in grade, stage and
PSA level to patients treated with surgery and may not be
comparable. From a small cohort of 26 patients who underwent
surgery for clinically localised disease, we recently showed that
those with the fusion expression had a significantly higher rate of
recurrence compared to patients who lacked the fusion expression
(5-year recurrence rate 79.5 vs 37.5%, P¼0.009) (Nam et al, 2007).
However, because the follow-up period was short (mean 12
months) and the sample size was small (n¼26), we could not
determine if this effect was independent of other factors, such as
grade, stage and PSA level. We also examined the significance of
ETV1 fusion, but did not find any association with cancer
recurrence (Nam et al, 2007).
Thus, it remains unclear whether the TMPRSS2:ERG gene fusion
is only a surrogate marker for established prognostic factors of
grade and stage, or whether it is an independent molecular-based
marker for disease recurrence with no association with grade or
stage, particularly for patients who are candidates for surgery for
clinically localised prostate cancer. To examine further these
associations, we sought the presence of TMPRSS2:ERG gene fusion
in 165 frozen prostate cancer samples from patients who under-
went radical prostatectomy for localised prostate cancer. We
compared the frequencies of TMPRSS2:ERG gene fusion status
between the clinicopathological variables of grade, stage and PSA
level. We also compared the rates of disease recurrence between
patients with and without the TMPRSS2:ERG gene fusion
expression.
MATERIALS AND METHODS
Study subjects
Patients were drawn from a series of 300 men who underwent
radical prostatectomy as the sole treatment for clinically localised
prostate cancer, between 1998 and 2006, at Sunnybrook Health
Sciences Center (Toronto, Canada). Since 1998 and with the
approval of the research ethics board, a prostate tumour tissue
bank was established. Prostate specimens were sampled at surgery
and immediately frozen. Patients were excluded for this study if
they used androgen deprivation therapy or chemotherapy before
surgery (n¼3) or if they were treated with adjuvant radiation or
androgen deprivation therapy (n¼21). For all patients the serum
PSA fell to an undetectable level (o0.02ngml
 1) following
surgery. Of the remaining 276 patients, 111 patients had cancer
cells that were not identified in the banked samples obtained from
the prostatectomy or insufficient tissue was available for RNA
extraction and RT–PCR analysis, leaving 165 patients available for
the follow-up analysis.
Prostate sample collection
All samples were taken from the prostate at the time of
prostatectomy. A section from the mid-portion of the prostate
was snap-frozen in liquid nitrogen and stored at  801C. The
majority of prostate tumours were not palpable within the
prostatectomy specimen, and therefore, the samples obtained
from the prostate were considered to be random. The banked slices
of specimens were photocopied, oriented (anterior, posterior, right
and left), quadrisected and cut in 5mm sections on the cryostat.
The sections were stained with H&E and then reviewed by the
pathologist (LS). The areas of tumour were marked on the stained
slides and on the photocopied diagram. The marked areas were
used to extract the tissue for total RNA extraction.
Total RNA was extracted from the frozen prostate cancer tissue
by homogenising in Trizol (Invitrogen Corporation, Carlsbad, CA,
USA) followed by ethanol precipitation. The RNA pellet was
dissolved in RNase-free H2O and quality was checked using 2100
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). All
tumour samples were obtained from the primary Gleason score
grade. For example, for a Gleason Score 7 (4þ3) tumour, samples
were obtained from the Gleason Grade 4 pattern.
RT–PCR and direct DNA sequencing
The presence of the TMPRSS2:ERG fusion gene was established
using RT–PCR for all 165 prostate cancer patient samples,
described elsewhere (Nam et al, 2007). Briefly, 1mg of total RNA
was reverse transcribed into cDNA using QuantiTect Reverse
Transcription Kit (Qiagen Inc., Valencia, CA, USA) in the presence
of random and oligo-dT primers. All reactions were performed
with both the forward and reverse primer sets (F-TAGGCGC
GAGCTAAGCAGGAG, R-GTAGGCACACTCAAACAACGACTGG)
that yields a 125-bp and (F-CAGGAGGCGGAGGCGGA, R-
GGCGGTTGTAGCTGGGGGTGAG) that yields a 595-bp product
as described by Tomlins et al (2005). PCR amplified products were
resolved by electrophoresis on a 2% agarose gels and bands were
excised, purified and sequenced using the ABI 3700 (Applied
Biosystems, Foster City, CA, USA) automated DNA sequencer
(Figure 1) (Nam et al, 2007).
Patient follow-up
Clinical data and follow-up informations were collected prospec-
tively. The medical records were systematically reviewed using
standardised data entry forms by trained data abstractors and
stored within a prostate cancer-specific database. Clinical follow-
up consisted of four assessments in the year following surgery, two
assessments in the second year and one assessment every year
thereafter. At each follow-up, patients had a clinical evaluation,
and a PSA test.
Data analysis
To determine whether or not TMPRSS2:ERG gene fusion was a
prognostic factor for cancer recurrence, we conducted a survival
analysis, from date of diagnosis to date of first biochemical
recurrence Biochemical recurrence was defined as a PSA increase
of at least 0.2ngml
 1 on at least two separate consecutive
measurements that are at least 3 months apart. The date of
recurrence was coded as the date of the first PSA recording of
X0.2ngml
 1. Patients were considered to be at risk from the date
of surgery until recurrence or until the date of the last PSA test.
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their last PSA test. Within the study period, only one patient died
(cause unrelated to prostate cancer). He was censored at the last
PSA test.
Rates of (biochemical) recurrence were compared between
patients with tumours that expressed TMPRSS2:ERG gene fusion
and with those who lacked the fusion product, using the Kaplan–
Meier method. The effect of TMPRSS2:ERG gene fusion was then
examined in a multivariable Cox proportional hazard model,
adjusting for age, grade, stage and PSA level at diagnosis.
Pathologic stage was categorised into three groups: (1) organ
confined; (2) extracapsular extension and (3) seminal vesicle
involvement (Nam et al, 2003). Histologic grade was categorised
into three groups: (1) Gleason Score 5 and 6; (2) Gleason Score 7
and (3) Gleason Score 8–10. Prostate-specific antigen level at
diagnosis was treated as a continuous variable. All data analysis
was conducted using the SAS System V9.1 (Carey, NC, USA).
RESULTS
Patient demographics and recurrence rates
The mean age at diagnosis of the 165 patients was 61.8 years
(s.d.¼7.4 years, range¼31–75 years). The distributions of
pathologic stage, margin status and PSA are described in Table 1.
Among the cohort, 44.1% of patients had cancers confined to the
prostate gland and the majority of cancers were of Gleason Score 7
(Table 1). The mean follow-up time was 28.4 months (range¼3–96
months). The overall median follow-up was 20 months. The
median follow-up in the fusion negative arm was 27 months and in
the fusion positive arm was 13 months. Of the 165 patients, 43
(26.1%) developed a biochemical recurrence, defined as a PSA
level of 40.02ngl
 1 on at least two separate consecutive
measurements that are at least 3 months apart. The crude 5-year
biochemical recurrence rate for the entire cohort was 33.8% (95%
CI¼25.0–44.8%).
Prognostic significance of TMPRSS2:ERG gene fusion
The presence of TMPRSS2 fusion with ERG in prostate cancer
samples was examined by RT–PCR of RNA for all cases. Prostate
samples from 81 of 165 (49.1%) patients were found to be positive
for fusion transcripts for the TMPRSS2:ERG fusion gene (Figure 1).
All fusion transcripts positive samples produced the expected 125
or 595bp bands depending upon which primer set used. DNA
sequencing indicated that most correspond to the fusion of
TMPRSS2 Exon 1 with Exon 4 of ERG transcript variant 2
(Genbank NM_00449). This fusion mRNA was reported to be the
most frequently observed fusion of the two genes, for it was found
in 490% of all tumours tested (Wang et al, 2006; Nam et al, 2007).
Among the 81 patients who had TMPRSS2:ERG fusion transcripts
within their tumour tissue, 37 (45.7%) experienced biochemical
recurrence, whereas among the 84 patients who had tumours that
lacked fusion, only six (7.1%) experienced a relapse (odds
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Figure 1 (A) DNA in agarose gel after TMPRSS2:ERG-specific RT–PCR
of RNA from primary prostate cancer tissue. Shown are PrR amplified
products, from a few representative cases, resolved by electrophoresis on a
2% agarose gels. Primer sets producing an expected size of 125bp poducts
are shown. (B) Schematic diagram and electropherograms of
TMPRSS2:ERG-specific RT–PCR amplified products. Diagramed are
TMPRSS2 and ERG variant 2 (Genbank NM_00449) gene exons and
fusion transcripts, with deleted exons in hatched colour, retained exons in
solid colour, and the fusion junction boxed. Shown is a fusion junction for
one of the cases, after electrophoresed DNA in bands (Figure 1A) was
excised, purified and sequenced using an ABI 3700 (Applied Biosystems)
automated DNA sequencer.
Table 1 Distribution of baseline factors of all patients and correlation between TMPRSS2:ERG gene fusion, histologic grade, pathologic stage and PSA
level at diagnosis
TMPRSS2:ERG gene fusion expression
Prognostic factor All patients (n¼165) Positive (n¼81) Negative (n¼84) P-value
Histologic grade
Gleason Score 5–6 41 21 (51.2%) 20 (48.7%) 0.67
Gleason Score 7 113 56 (49.6%) 57 (50.4%)
Gleason Score 8–10 11 4 (36.3%) 7 (63.6%)
Pathologic stage
Organ confined 74 35 (47.3%) 39 (52.7%) 0.92
Extracapsular extension 79 40 (50.6%) 39 (49.4%)
Seminal vesicle involvement 12 6 (50%) 6 (50%)
PSA level at diagnosis (ngml
 1)
Mean (s.d.) 9.3 (7.3) 9.5 (5.7) 9.1 (8.6) 0.73
Median 7.3 8.0 7.0 0.14
Range 2.1–64 3.0–38.9 2.1–64
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 7). On the basis of the
Kaplan–Meier survival estimates, the group of patients who had
tumours with TMPRSS2:ERG gene fusion had a much greater rate
of recurrence at 5 years (58.4%) than patients who lacked the
fusion gene (8.1%; Po0.0001) (Figure 2).
In the univariable analysis, TMPRSS2:ERG fusion was a strong
predictor for disease recurrence (hazard ratio¼8.2, 95% CI¼3.4–
19.5, Po0.0001) (Table 2). The established prognostic factors of
histologic grade, pathologic stage and PSA level at diagnosis were
also significant predictors for disease recurrence (Table 2). After
adjustment for these factors, the prognostic importance of the
fusion protein was not diminished (hazard ratio¼8.6; 95%
CI¼3.6–20.6, Po0.0001) (Table 2). Among the prognostic factors,
only grade and fusion status were significant predictors for disease
recurrence. Of the two, fusion gene status had a stronger effect on
disease recurrence than did each incremental increase in grade
category (hazard ratios¼8.5 and ¼6.3, respectively).
To determine whether or not the presence of the TMPRSS2:ERG
fusion correlated with other prognostic factors, we compared the
proportions of patients with the gene fusion in patient subgroups
defined by grade, stage and PSA level. The proportions were
similar in each grade and stage category, and the distribution of
PSA levels did not significantly differ between patients with or
without fusion (Table 1). Also, of the six patients who recurred
without any evidence of fusion, five of the six patients had a
Gleason Score of 7 or more.
We examined further whether TMPRSS2:ERG gene fusion was
predictive of recurrence stratified by grade and stage. The 5-year
recurrence-free survival for patients with Gleason Score 5–6, 7 and
8–10 were 76.1 (95% CI¼53.4–88.7%), 64.0% (95% CI¼50.1–
74.9%) and 48.5% (95% CI¼8.8–80.6%), respectively. For all
grade categories, patients with TMPRSS2:ERG gene fusion was
associated with increased risk for recurrence (Table 3). Similarly,
patients with gene fusion had a higher risk for recurrence for all
stage categories (Table 3).
DISCUSSION
We have identified an important genetic-based prognostic factor
for prostate cancer recurrence among patients who are treated for
clinically localised cancer with surgery alone. Since Tomlins et al
(2005) first described the association between TMPRSS2:ERG gene
fusion expression and prostate cancer, several other studies have
addressed the potential clinical implications of the discovery. All
case–control studies (Perner et al, 2006; Wang et al, 2006) did not
show associations with disease recurrence, but did show correla-
tions with stage or grade. Perner et al (2006) studied 118 prostate
cancer samples from various prostate cancer groups at different
stages using FISH and found 60.3% of patients with fusion and a
significant correlation was found with stage at diagnosis. Wang
et al (2006) identified the presence of fusion using RT–PCR in
59% of patients, but no correlation with prostate cancer recurrence
was identified. However, in their study, cases and controls were
not derived from the same source. From a case–control study by
Lapointe et al (2007), where 54 patients with localised cancer and
9 patients with metastasis were examined for fusion status, no
correlations were found with stage, grade or recurrence. On the
other hand, large cohort studies of patients managed with watchful
waiting did show correlations with a positive fusion status being
associated with reduced survival (Attard et al, 2007; Demichelis
et al, 2007).
In the current study, neither grade, stage nor PSA level
correlated with the presence of TMPRSS2:ERG gene fusion. This
could be due to insufficient power to examine for these multiple
comparisons. However, the distribution of gene fusion expression
by grade, stage and PSA are highly similar between the fusion
positive and negative patients, and the Kaplan–Meier recurrence
rates were different by fusion expression for each category of grade
and stage (Table 3). Further, Mosquera et al (2007) showed from
morphological analysis of tumour tissue that gene fusion
expression was correlated to other histologic features, and not
related to Gleason grading or pathologic staging. This suggests a
unique biologic mechanism that requires further elucidation. Our
results would be consistent with these findings.
In the multivariable analysis, gene fusion was the strongest
predictor for disease recurrence followed by grade. We could not
examine for potential statistical interaction due to our sample size,
which could be responsible for the changes in value of the hazard
ratios in the multivariable analysis. Before this study, tumour
grade was considered to be the most important prognostic factor
(Barry et al, 2001). Within our model, grade was still an important
factor, but the relative risk for recurrence was more marked for
TMPRSS2:ERG gene fusion status than for grade. Indeed, of the six
patients who recurred without fusion, five of them had a Gleason 7
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Figure 2 Kaplan–Meier survival estimates for patients with and without TMPSSR2:ERG gene fusion using biochemical recurrence as the primary end
point.
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Score 6 tumours.
A limitation to our study is the use of PSA recurrence as the
primary end point. It would be ideal to use prostate cancer-specific
mortality. Prostate-specific antigen recurrence (40.2ngml
 1) has
been shown to be surrogate marker for prostate cancer-specific
mortality from large, independent cohorts (Walsh et al, 1994;
Zincke et al, 1994; Pound et al, 1999; D’Amico et al, 2003). Pound
et al (1999) showed that patients initially described by Walsh
(1994) who develop a PSA recurrence after surgery develop
metastasis over a median time of 8 years. Zincke et al (1994)
compared PSA recurrence rates, cause-specific mortality and
overall survival among 3170 patients treated with surgery and
found strong and consistent correlations between these outcome
variables and grade, stage and PSA level. D’Amico et al (2003)
further showed that higher rates of PSA rise after surgery or
radiation was associated with earlier prostate cancer-specific
death. Because we used PSA recurrence as our end point, patients
who received neoadjuvant or adjuvant treatments were excluded
given that the time to PSA recurrence may be biased, introducing
potential selection bias. A larger cohort with longer follow-up for
prostate cancer mortality will be needed to closely examine these
relationships with gene fusion expression.
Another limitation was that the majority of our patients had
Gleason Score 7 cancer and few patients had tumours of Gleason
score 6 or less. This is likely due to tumour sampling at the time of
prostatectomy; patients with Gleason Score 6 or less in general
have a lower volume of cancer and the probability of sampling the
cancer would therefore be lower than for patients with cancers of
Gleason 7 or more. This resulted in a large number of patients
being excluded which is likely responsible for the high rate of
recurrence found from this study. Current methods in examining
for expression of gene fusion are limited to frozen tissue, which is
susceptible to tumour sampling error. Future studies should be
able to overcome this limitation, such as analysing RNA from
paraffin-embedded samples or immunohistochemistry. Never-
theless, the prognostic significance of grade, stage and PSA level
in the current study are similar to the findings of other larger,
contemporary series in North America (Barry et al, 2001).
Many other rare transcripts of this gene fusion have been
described (Soller et al, 2006; Wang et al, 2006; Clark et al, 2007; Liu
et al, 2007; Tu et al, 2007). We only examined the most common
fusions of TMPRSS2 exon 1 with exon 4 of ERG transcript.
Alternative fusions are possible, but having two or more distinct
translocations on each allele in a single tumour area is not likely
rather, these transcripts may arise from alternative splicing of the
Table 2 Univariable and multivariable Cox regression analysis of pathologic stage, margin status, PSA level at diagnosis and TMPRSS2:ERG gene fusion
Covariate Crude hazard ratio 95% CI P-value Adjusted hazard ratio 95% CI P-value
Histologic grade
Gleason Scorep6 1.0 1.0
Gleason Score 7 1.9
a 0.9–4.2 0.11 1.8
a 0.8–3.9 0.17
Gleason Score 8–0 4.6
a 1.3–16.0 0.02 6.3
a 1.7–23.6 0.006
Pathologic stage
Organ confined 1.0 1.0
Extracapsular extension 1.9 0.9–4.2 0.11 1.1 0.6–2.2 0.77
Seminal vesicle Involvement 4.6 1.3–16.0 0.01 1.4 0.5–4.4 0.54
PSA 1.04
b 1.0–1.1 0.01 1.02 0.9–1.1 0.30
TMPRSS2:ERG Gene fusion expression
Negative 1.0 1.0
Positive 8.2 3.4–19.5 o0.0001
c 8.6 3.6–20.6 o0.0001
c
aTest for trend, w
2¼5.4, P¼0.02 for crude; and w
2¼5.6, P¼0.02 for adjusted value.
bHazard ratio based on per unit (ngml
 1) increase in PSA level.
cw
2 (1d.f.)¼22.5 for crude
and 22.6 for adjusted hazard ratio.
Table 3 Five-year Kaplan–Meier (KM) biochemical survival estimates by TMPRSS2:ERG gene fusion status stratified by histologic grade and pathologic
stage
TMPRSS2:ERG fusion status
Positive Negative
Prognostic factor Number of Events
5-year KM biochemical
survival rate (median
follow-up months) Number of events
5-year KM biochemical
survival rate (median
follow-up months) P-value*
Grade
Gleason Score 5–6 7/21 (33.3%) 60.6% (20) 1/20 (5.0%) 93.3% (24) 0.02
Gleason Score 7 27/56 (48.2%) 37.6% (12) 4/57 (7.0%) 92.5% (29) o0.0001
Gleason Score 8–10 3/4 (75.0%) 0.0% (5) 1/7 (14.3%) 85.7% (10) 0.07
Stage
Organ confined 12/35 (34.3%) 59.0% (20) 4/39 (10.3%) 85.7% (26) 0.007
Extraprostatic
extension
21/40 (52.5%) 27.0% (12) 1/39 (2.6%) 100.0% (34) o0.0001
Seminal vesicle
involvement
4/6 (66.7%) 0.0% (6) 12/35 (34.3%) 83.3% (7) 0.13
*P-value based on Kaplan–Meier log-rank test for significance.
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sfused exons, after transcription. Alternative splicing of ERG gene is
well studied, with up to 17 variants being described (Soller et al,
2006; Clark et al, 2007). Several studies have consistently confirmed
that fusion at exon 1 of TMPRSS2 is the most common variant (Tu
et al, 1996; Wang et al, 2006; Clark et al,2 0 0 7 ) .H o w e v e r ,C l a r ket al
(2007) also found that distinct patterns of hybrid transcripts from
separate areas of the same tumour which would make associations
of clinical significance more difficult. These and other separate
fusion transcripts will require further study to examine for their
association with prostate cancer prognosis.
If these findings are confirmed, they might have an important
impact on the treatment of clinically localised prostate cancer. In a
randomised trial, Bill-Axelson et al (2005) showed that patients
who had prostatectomy had a better cancer-specific survival than
did patients who did not undergo surgery for clinically-localised
prostate cancer. However, the gains in life expectancy and survival
associated with surgery were small. Using TMPRSS2:ERG gene
fusion status to differentiate between patients who are at high risk
for disease progression may eventually help to identify patients
who would benefit the most from treatment.
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